Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naglazyme Post-Allo Transplant for MPS VI
NCT02156674Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of galsulfase in mucopolysaccharidosis type VI, sponsored by Masonic Cancer Center. Primary endpoints: Change in Urinary Glycosaminoglycan (GAG) Excretion at 2 years, Change in Distance Traveled at 2 years and 1 more. Started Jan 2016; status: terminated.
02
Drugs
galsulfase
03
Conditions
mucopolysaccharidosis type VI
Beyond the preview
Go deeper on NCT02156674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156674.